

Improving a process to obtain hepatitis B serology among patients treated with infliximab at a large urban children's hospital

M Raphaëlle Jean,¹ Ann Weaver,¹ Teresa Mastin-Diebold,¹ Krista Kissinger,¹ Emily A Smitherman,² Leslie Favier,² Lara Danziger-Isakov,³ Elizabeth Williams,¹ Rebecca C Brady,³ Jennifer Huggins,² Lee A Denson,¹ Shehzad A Saeed,¹ Pamela Morgan,¹ Dana Michelle Hines Dykes¹

To cite: Jean MR, Weaver A, Mastin-Diebold T, *et al*. Improving a process to obtain hepatitis B serology among patients treated with infliximab at a large urban children's hospital. *BMJ Open Quality* 2017;6:e000092. doi:10.1136/bmjopen-2017-000092

Received 21 April 2017

Revised 5 September 2017

Accepted 23 September 2017

ABSTRACT

Background Hepatitis B infection is a significant public health challenge despite improvements in vaccination efforts. Patients such as those on chronic immunosuppressive therapy for inflammatory bowel disease (IBD) or rheumatic disease may incur greater risk. The risk of reactivation of hepatitis B while on immunosuppressive therapy may have mortality rates up to 25%. These patients should be screened for acute or chronic infection and vaccinated if necessary. Our aim was to reliably complete hepatitis B screenings in patients receiving infliximab at Cincinnati Children's Hospital Medical Center (CCHMC).

Methods Eligible patients included all patients with gastroenterology (GI) IBD and rheumatology receiving infliximab between October 2015 and March 2016. Using quality improvement methodology and the 'plan-do-study-act' (PDSA) approach, interventions centred around education of clinical providers, previsit planning and the development of 'talking points' for patients.

Results An initial screen of the IBD population revealed that 48% of the IBD patient population had been screened for anti-HBs alone, but no patients from GI or rheumatology divisions had a complete set of hepatitis B serology prior to the intervention including anti-Hep B Core and Hep B Surface Antigen. Seven PDSA cycles were performed during the 32-week intervention period, resulting in an increase in patients screened from 0% to ~85%. By March 2016, a total of 251 patients (201 GI, 50 rheumatology) had up-to-date hepatitis B serology screening. Automated ordering of the hepatitis B serology and 'talking points' for the provider had the greatest impact on successful screening.

Conclusions We developed a method to obtain hepatitis B serology on at-risk patients on infliximab within two subspecialty divisions within a large children's hospital. Next steps will be to develop a process to reliably provide vaccines for patients who are seronegative, expand this process to all patients who are identified as immunocompromised within GI and rheumatology and then expand this process to other divisions at the CCHMC.

PROBLEM

Current guidelines suggest monitoring for hepatitis B immunity and attempting to ensure adequate immunity for patients on chronic immunosuppressive therapy, ideally prior to the start of these therapies, with particular attention to those on biologics such as infliximab.¹ In our gastroenterology (GI) inflammatory bowel disease (IBD) and rheumatology programme at Cincinnati Children's Hospital Medical Center (CCHMC), we have identified a gap in our ability to reliably assess for hepatitis B virus (HBV) immunity and to properly ensure that patients who are lacking appropriate immune response receive appropriate booster vaccinations. Our aim was to develop a process to reliably complete HBV screenings on patients receiving infliximab within the paediatric GI and rheumatology divisions at the CCHMC. A search in the electronic medical record shared by the hospital found that of the 598 patients with IBD at the CCHMC, only 48% (n=286) have been screened for HBV immunity using anti-HBs alone (figure 1), and of these only 35% (n=101) of the patients who were screened had documented immunity to HBV. Among our 62 rheumatology patients on infliximab, the majority of whom are diagnosed with juvenile idiopathic arthritis, there also was no set process to identify and screen them for hepatitis B immunity. None of these patients had a complete set of hepatitis B titres which also included Hep B Core antibody (anti-HBc) and Hep B Surface Antigen (HBsAg). We intended to use quality improvement methodology to improve hepatitis B screening and



CrossMark

¹Division of Pediatric Gastroenterology, Hepatology, and Nutrition, Department of Pediatrics, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, USA

²Division of Rheumatology, Department of Pediatrics, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, USA

³Division of Infectious Diseases, Department of Pediatrics, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, USA

Correspondence to

Dr Dana Michelle Hines Dykes; chellydykes@gmail.com




Figure 1 Anti-HB screening assessment among entire inflammatory bowel disease (IBD) patient population at the Cincinnati Children's Hospital Medical Center.

ultimately vaccination rates for this vulnerable population.

BACKGROUND

Autoimmune conditions requiring immune suppression are among the most common chronic diseases in paediatric gastroenterology and rheumatology practices. Conditions such as ulcerative colitis and Crohn's disease, collectively referred to as IBDs, as well as juvenile idiopathic arthritis are chronic inflammatory disorders encountered frequently in paediatrics.² These diseases are debilitating conditions with unpredictable courses and challenging treatments.^{2,3} Although immunosuppressive medications have resulted in improved outcomes, these therapies may place patients at increased risk of complications from potentially preventable infections such as hepatitis B.⁴⁻⁶




Figure 2 Key driver diagram for hepatitis B screening. CCHMC, Cincinnati Children's Hospital Medical Center; HBV, hepatitis B virus; IBD, inflammatory bowel disease.

Vaccination for hepatitis B is currently performed in infancy, but can be completed later in life if necessary. Currently both licensed single-antigen hepatitis B vaccines administered intramuscularly produce a >95% sero-protection rate in adolescents.⁵ During 1995–2005, incidence of acute hepatitis B in the USA among children and adolescents declined by 94%, coincident with an increase in hepatitis B vaccination coverage.⁵ Immunocompetent persons, even those vaccinated during infancy, who achieve appropriate anti-HBs concentrations (>10 mIU/mL) after vaccination have virtually complete protection against both acute disease and chronic infection even if anti-HBs concentrations subsequently decline to <10 mIU/mL.⁷⁻¹¹ Some vaccinations such as the hepatitis B vaccine may be less effective in patients with underlying immune conditions or who are already receiving immune suppressive therapy, in which a reduced persistence of immunological memory may be seen over time.^{6,12} Although immunogenicity is lower among immunocompromised persons, those who achieve and maintain a protective antibody response before exposure to HBV have a high level of protection from infection.⁵

Despite the above improvements in vaccination efforts, hepatitis B infection remains a significant public health challenge. For patients receiving biological therapies such as anti-tumour necrosis factor alpha treatments, reactivation or newly acquired hepatitis B infection can be associated with an abrupt increase in HBV replication, jaundice, elevated serum aminotransferase levels and can pose a significant risk of morbidity and mortality in patients receiving these agents, with mortality rates reported as high as 25%.¹³⁻¹⁶ One cross-sectional single-centre study evaluating 100 paediatric IBD patients on infliximab at a large, urban tertiary care facility demonstrated that a significant minority (13%) of study participants had not been vaccinated against the HBV and an additional 44% of previously vaccinated patients lacked protective anti-HBs levels.⁴ Among these non-immune patients receiving HBV immunisation, only 14% of patients appeared at risk for HBV infection due to inability to elicit immunity to the virus.¹¹ Given risk of severe disease if affected, vaccination screening and immunisation for patients without protective antibodies represents an opportunity for disease prevention in this vulnerable population even if they have already started infliximab.

BASELINE MEASUREMENT

Our first baseline measurement was performed using the larger IBD population rather than the smaller rheumatology patients and found that in a population of 598 patients <50% (286) had been screened with anti-HBs alone (figure 1). We chose to narrow our scope to both rheumatology and gastroenterology patients receiving infliximab (n=237) since these were viewed as the highest risk patients and were followed up most regularly and




Figure 3 Analytic tools to design and measure improvements. (A) Failure mode analysis for hepatitis B screening. (B) Pareto chart demonstrating the most common hepatitis B screening process failures within the inflammatory bowel disease (IBD) and rheumatology population. (C) Hepatitis B screening/immunisation process map.

rapidly for reassessment (every 4–8 weeks for infusions). Among the population receiving infliximab, we documented complete screening serology (including anti-HBc, anti-HBs and HBsAg) in 0% of patients at the onset of the project. Our team's specific, measurable, achievable, realistic, timely (SMART) aim was that by March 2016 we would increase the per cent of complete HBV screenings (all three titres) each week from 0% to 80% among patients with IBD and rheumatology receiving infliximab infusions at the CCHMC. Our global/long-term aim is to increase HBV immunity for immunocompromised patients seen at the CCHMC by improving vaccination rates for at-risk patients.

DESIGN


Prior to making changes to the current system, we identified key drivers that would optimise our system's ability to achieve and maintain a process for monitoring and improving hepatitis B screening and immunity (figure 2). These drivers included an informed and activated team, a clearly identified population, timely and accurate recognition of results, standardised and complete care, appropriate communication with healthcare partners and patient access to the care team.

Initial steps prior to designing interventions centred around a formal failure analysis (figure 3A), Pareto analysis (figure 3B) and process map of the hepatitis B

screening process (figure 3C). Opportunities for improvement included education, appropriate and timely recognition of at-risk patients, and building standardisation and automation into the current processes.

The main interventions included re-screening/pre-screening infliximab infusion patients, creation and implementation of a fact sheet on HBV reactivation prevention (which included a standardised algorithm), Epic build of an automated list to identify at-risk patients, and the creation and implementation of a health maintenance previsit planning (PVP) form to be used in our cohort of infliximab infusion patients and ultimately all clinic patients. Prior to beginning the above interventions, early plan-do-study-act (PDSAs) were completed using education/information sessions with GI/rheumatology medical providers to increase their knowledge regarding the improvement project goals and objectives. These sessions were repeated periodically throughout the 6-month timeline of the project and repeated or altered if gaps in medical providers' understanding of the project objectives were identified.

The backbone of the HBV screening process for our patients on infliximab therapy is founded in the integration of multiple PDSAs which worked well as a bundle (education, automated list, previsit order entry) and has led to the development of an automated system to be incorporated into routine clinical practice through PVP.



50%. Further work will continue to evaluate the success of immunisation in these patients and will be expanded to patients who may not have initiated immunosuppressive medications like infliximab, which may result in reduced responsiveness to the vaccine.

LESSONS AND LIMITATIONS

One of the major limitations encountered in the system revolved around difficulty integrating knowledge of guidelines for immunisation screenings into daily clinical care. Repeated exposure with information, simplified processes and reminders, as well as simplifying order entry have all helped with buy-in and are now a part of expected and routine care within the GI and rheumatology divisions.

Another major limitation surrounded the lack of automated processes. Successful PDSAs reduced cumbersome extra steps, eliminated the need for providers or patients to recall steps on their own and allowed for automated process completion rather than manual work. At the completion of the hepatitis B improvement work, there remain a number of steps that are not automated and include automatic order entry by clinic staff (which has been beneficial for other vaccine projects in our clinics), as well as communication with primary physician regarding vaccine administration which will continue to be part of future work. While this project achieved its aim, the weekly patient identification and screenings, automated patient lists, easy-to-use order sets and immunisation algorithms have served as a starting point for other work aimed at centralising and incorporating other health maintenance improvement projects into one simple process for all patients at every planned encounter.

CONCLUSIONS

We demonstrated that by providing education and achieving consensus surrounding hepatitis B screening, automating processes and simplifying algorithms for testing and order entry, we could improve the implementation of recommended screening guidelines for hepatitis B immunity in at-risk patients receiving infliximab in paediatric IBD and rheumatic disease populations. Subsequent work is being developed using PDSAs from the hepatitis B screening process including previsit automated patient identification, and screening and vaccination algorithm. We will continue to work to integrate this work with other ongoing improvement projects in an effort to create a centralised and automated health maintenance supervision process for our clinic and infusion visits.

Acknowledgements This work was completed due to support from the NIH Training grant T32 DK007727.

Contributors Conception or design of the work: LAD, DMHD, MRJ, AW and TM-D. Data collection: MRJ, DMHD, AW, TM-D, KK, PM, JH, EAS, LF and EW. Data analysis and interpretation: MRJ, DMHD, LAD, PM, AW, TM-D, JH, EAS, LF and EW. Drafting the article: MRJ and DMHD. Critical revision of the article: DMHD, LAD, SAS, JH, EAS, LF, RCB and LDI. Final approval of the version to be published: DMHD, SS, LAD and MRJ.

Funding NIH T32 DK007727 PI Dr Lee A Denson; Pfizer 15448819 PI Dr Rebecca Brady.

Provenance and peer review Not commissioned; externally peer reviewed.

Open Access This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>

© Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to <http://www.bmj.com/company/products-services/rights-and-licensing/>

REFERENCES

1. Rufo PA, Denson LA, Sylvester FA, *et al.* Health supervision in the management of children and adolescents with IBD: NASPGHAN recommendations. *J Pediatr Gastroenterol Nutr* 2012;55:93–108.
2. Weiss JE, Ilowite NT. Juvenile idiopathic arthritis. *Rheum Dis Clin North Am* 2007;33:441–70.
3. Karwowski CA, Keljo D, Szigethy E. Strategies to improve quality of life in adolescents with inflammatory bowel disease. *Inflamm Bowel Dis* 2009;15:1755–64.
4. Moses J, Alkhouri N, Shannon A, *et al.* Hepatitis B immunity and response to booster vaccination in children with inflammatory bowel disease treated with infliximab. *Am J Gastroenterol* 2012;107:133–8.
5. Mast EE, Margolis HS, Fiore AE, *et al.* A comprehensive immunization strategy to eliminate transmission of hepatitis B virus infection in the United States: recommendations of the Advisory Committee on Immunization Practices (ACIP) part 1: immunization of infants, children, and adolescents. *MMWR Recomm Rep* 2005;54:1–31.
6. Groot N, Heijstek MW, Wulffraat NM. Vaccinations in paediatric rheumatology: an update on current developments. *Curr Rheumatol Rep* 2015;17:46.
7. Szmunes W, Stevens CE, Harley EJ, *et al.* Hepatitis B vaccine: demonstration of efficacy in a controlled clinical trial in a high-risk population in the United States. *N Engl J Med* 1980;303:833–41.
8. Francis DP, Hadler SC, Thompson SE, *et al.* The prevention of hepatitis B with vaccine. Report of the centers for disease control multi-center efficacy trial among homosexual men. *Ann Intern Med* 1982;97:362–6.
9. Hadler SC, Francis DP, Maynard JE, *et al.* Long-term immunogenicity and efficacy of hepatitis B vaccine in homosexual men. *N Engl J Med* 1986;315:209–14.
10. Jack AD, Hall AJ, Maine N, *et al.* What level of hepatitis B antibody is protective? *J Infect Dis* 1999;179:489–92.
11. Spada E, Romanò L, Tosti ME, *et al.* Hepatitis B immunity in teenagers vaccinated as infants: an Italian 17-year follow-up study. *Clin Microbiol Infect* 2014;20:O680–O686.
12. Gisbert JP, Villagrasa JR, Rodríguez-Nogueiras A, *et al.* Efficacy of hepatitis B vaccination and revaccination and factors impacting on response in patients with inflammatory bowel disease. *Am J Gastroenterol* 2012;107:1460–6.
13. Millonig G, Kern M, Ludwiczek O, *et al.* Subfulminant hepatitis B after infliximab in Crohn's disease: need for HBV-screening? *World J Gastroenterol* 2006;12:974–6.
14. Ojio K, Naganuma M, Ebinuma H, *et al.* Reactivation of hepatitis B in a patient with Crohn's disease treated using infliximab. *J Gastroenterol* 2008;43:397–401.
15. Esteve M, Saro C, González-Huix F, *et al.* Chronic hepatitis B reactivation following infliximab therapy in Crohn's disease patients: need for primary prophylaxis. *Gut* 2004;53:1363–5.
16. Di Bisceglie AM, Lok AS, Martin P, *et al.* Recent US Food and Drug Administration warnings on hepatitis B reactivation with immune-suppressing and anticancer drugs: just the tip of the iceberg? *Hepatology* 2015;61:703–11.